Hair care and hair loss prevention composition and application thereof

Abstract

The invention discloses a hair care and hair loss prevention composition and application thereof, and the composition contains cationic hyaluronic acid or simultaneously contains cationic hyaluronic acid and ergothioneine. Experiments prove that the cationic hyaluronic acid has a synergistic effect when promoting hair growth, and the ergothioneine and the cationic hyaluronic acid have a synergistic effect when being compounded to promote hair growth.

Description

Technical Field

[0001] The invention relates to a hair care and hair loss prevention composition, and also relates to the application of the composition in the hair loss prevention and hair care fields. Background Art

[0002] As we age or are affected by certain diseases, our hair will gradually fall out and become sparse. In recent years, the problem of hair loss has become younger, and hair loss is often related to a variety of factors, such as genetics, hormonal imbalance, malnutrition, and excessive psychological stress. To solve the problem of hair loss, we first need to maintain a healthy lifestyle, and secondly, avoid excessive use of chemical products such as hair dyes and perms on the hair and scalp. In addition, the use of medications and lotions can help reduce hair loss and promote hair growth. In short, solving the problem of hair loss requires taking corresponding treatment methods for different types of hair loss causes. Only in this way can we have healthy and thick hair.

[0003] Dermal papilla cells are located at the root of hair follicles. During the hair growth period, dermal papilla cells proliferate rapidly and provide nutrition for hair growth. Vascular endothelial growth factor VEGF in dermal papilla cells plays a role in nutrition supply and can effectively promote the formation of capillaries. Increased VEGF content can provide more abundant nutrition for hair follicles, promote the proliferation of dermal papilla cells, and thus achieve the effect of strengthening hair and promoting hair growth. Androgen DHT inhibits cell growth, resulting in a decrease in the ability of cells to secrete growth factor VEGF, thereby affecting the normal growth of hair. Therefore, promoting the increase in the content of growth factor VEGF secreted by cells is also an effective way to promote hair growth. Summary of the invention

[0004] The invention aims to provide a hair care and anti-hair loss composition, wherein the composition contains cationic hyaluronic acid, and experiments have shown that the cationic hyaluronic acid has a synergistic effect in promoting hair growth. The composition compounds ergothioneine with the cationic hyaluronic acid, and exhibits a synergistic effect of promoting the secretion of vascular endothelial growth factor (VEGF).

[0005] A hair care and anti-hair loss composition comprises cationic hyaluronic acid, wherein the cationic hyaluronic acid may be one kind or two or more kinds.

[0006] Furthermore, the composition also includes ergothioneine.

[0007] Further, the mass ratio of cationic hyaluronic acid and thioneine is 1:0.2-5.

[0008] Furthermore, the above composition also includes pharmaceutically acceptable excipients.

[0009] Furthermore, the above composition also includes auxiliary materials and / or active ingredients acceptable in cosmetics.

[0010] The present invention also provides the use of cationic hyaluronic acid in preparing a product for promoting the secretion of vascular endothelial growth factor (VEGF).

[0011] The present invention also provides application of a combination of cationic hyaluronic acid and ergothioneine in preparing a product for promoting secretion of vascular endothelial growth factor (VEGF).

[0012] The present invention also provides the use of cationic hyaluronic acid and / or a combination of cationic hyaluronic acid and ergothioneine and / or the above-mentioned hair care and anti-hair loss composition in the preparation of hair care, hair loss prevention or / and hair growth promotion products.

[0013] The present invention also provides a method for hair care and / or hair loss prevention and / or hair growth promotion, comprising administering cationic hyaluronic acid or the above-mentioned hair care and hair loss prevention composition to a subject.

[0014] The present invention has been experimentally verified to find that in a hair papilla cell model stimulated by the androgen DHT, cationic hyaluronic acid and a combination of ergothioneine and cationic hyaluronic acid have a significant synergistic effect in promoting the increase in the content of vascular endothelial growth factor VEGF, showing potential application value in hair loss prevention, hair care or hair growth promotion products. DETAILED DESCRIPTION

[0015] The present application is further described below in conjunction with examples. It should be understood that the examples are only used to further describe and illustrate the present application and are not used to limit the present application.

[0016] Unless otherwise defined, the technical and scientific terms in this specification have the same meaning as those generally understood by those skilled in the art. Although similar or identical methods and materials as described herein may be used in experiments or actual uses, the materials and methods are described herein below. In the event of a conflict, the present specification including the definitions therein shall prevail. In addition, the materials, methods and examples are for illustration only and are not limiting. The present application is further described below in conjunction with specific examples, but is not intended to limit the scope of the present application.

[0017] The invention provides a hair care and hair loss prevention composition, wherein the active component of the composition contains cationic hyaluronic acid.

[0018] Cationic hyaluronic acid, also known as hydroxypropyltrimethylammonium chloride hyaluronic acid, is formed by grafting hydroxypropyltrimethylammonium chloride onto hyaluronic acid through a chemical grafting process and can be purchased directly from the market. Cationic hyaluronic acid has the natural moisturizing effect of hyaluronic acid and can provide long-lasting moisturizing effects for skin and hair. In addition, the positive charge in cationic hyaluronic acid combines with the negative charge in hair, which has antistatic properties.

[0019] Experimental verification shows that cationic hyaluronic acid has a better effect in promoting the secretion of vascular endothelial growth factor (VEGF) than a physical mixture of simple hyaluronic acid and hydroxypropyltrimethylammonium chloride, and has a significant synergistic effect.

[0020] Furthermore, there is no special requirement for the content of cationic hyaluronic acid in the composition, as long as the cationic hyaluronic acid can promote the secretion of vascular endothelial growth factor VEGF. In a specific embodiment of the present invention, the content of cationic hyaluronic acid in the composition is 0.1wt%-0.6wt%, such as 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%.

[0021] In a specific embodiment of the present invention, the molecular weight of the cationic hyaluronic acid is 50kDa-1500kDa, for example 50kDa, 100kDa, 150kDa, 200kDa, 250kDa, 300kDa, 350kDa, 400kDa, 450kDa, 500kDa, 550kDa, 600kDa, 650kDa, 700kDa, 750kDa, 800kDa, 850kDa, 900kDa, 950kDa, 1000kDa, 1050kDa, 1100kDa, 1150kDa, 1200kDa, 1250kDa, 1300kDa, 1350kDa, 1400kDa, 1450kDa, 1500kDa.

[0022] In a specific embodiment of the present invention, the degree of substitution of cationic hyaluronic acid is 1-40wt%, for example 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%.

[0023] Furthermore, the active ingredient in the above composition also contains ergothioneine. Experimental verification shows that the combination of ergothioneine and cationic hyaluronic acid shows a more obvious synergistic effect.

[0024] Ergothioneine (EGT) is a common antioxidant. In addition to its excellent antioxidant activity, it also has anti-inflammatory and whitening effects.

[0025] In a specific embodiment of the present invention, ergothioneine is introduced in a pure form.

[0026] In a specific embodiment of the present invention, the mass ratio of cationic hyaluronic acid and ergothioneine is 5:1-1:5, for example 5:1, 4:1, 3:1, 2:1, 1:1, 1:2, 1:3, 1:4, 1:5.

[0027] Further, the content of cationic hyaluronic acid and thioneine in the composition has no special requirements, as long as they can play the role of promoting the secretion of vascular endothelial growth factor VEGF. In a specific embodiment of the present invention, the total amount of cationic hyaluronic acid and thioneine in the composition is 0.1wt%-0.6wt%, such as 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%.

[0028] In a specific embodiment of the present invention, in addition to cationic hyaluronic acid and ergothioneine, the above-mentioned composition also includes pharmaceutically acceptable excipients, such as excipients, solubilizers, cosolvents, sustained-release agents, stabilizers, pH regulators, solvents, etc. required for making various dosage forms.

[0029] In a specific embodiment of the present invention, the above composition, in addition to cationic hyaluronic acid and ergothioneine, further comprises cosmetically acceptable auxiliary materials and / or other active ingredients.

[0030] Furthermore, the acceptable auxiliary materials in the cosmetics include, but are not limited to, one or more of preservatives, fragrances, thickeners, cosolvents, oils, solvents, pH adjusters, and the like.

[0031] Further, the other active ingredients can be active ingredients commonly used in the cosmetics field, such as moisturizing ingredients, anti-inflammatory ingredients, antioxidant ingredients, hair care ingredients, anti-hair loss ingredients, etc. The addition of these active ingredients will not affect the performance of the secretion effect of vascular endothelial growth factor VEGF of cationic hyaluronic acid and ergothioneine.

[0032] Furthermore, the composition is an external product, which can be a medicine or a hair care or anti-hair loss cosmetic. It can be made into various dosage forms, such as hair conditioner, shampoo, spray, drops, ointment, etc.

[0033] The present invention also provides the use of cationic hyaluronic acid in preparing a product for promoting the secretion of vascular endothelial growth factor (VEGF).

[0034] The present invention also provides the use of cationic hyaluronic acid in preparing hair care, hair loss prevention or / and hair growth promotion products.

[0035] The present invention also provides application of a combination of cationic hyaluronic acid and ergothioneine in promoting the secretion of vascular endothelial growth factor (VEGF).

[0036] The present invention also provides the use of a combination of cationic hyaluronic acid and ergothioneine in preparing a hair care, hair loss prevention or / and hair growth promotion product.

[0037] Further, in the combination of cationic hyaluronic acid and ergothioneine, the mass ratio of cationic hyaluronic acid and ergothioneine is 1:0.2-5.

[0038] The present invention also provides the use of the hair care and hair loss prevention product in preparing hair care, hair loss prevention or / and hair growth promotion products.

[0039] Furthermore, the hair care, hair loss prevention and / or hair growth promotion product is a medicine or a cosmetic.

[0040] The present invention also provides a method for hair care and / or hair loss prevention and / or hair growth promotion, comprising administering cationic hyaluronic acid or the above-mentioned hair care and hair loss prevention composition to a subject.

[0041] Example

[0042] The present invention generally and / or specifically describes the materials and experimental methods used in the experiments. In the following examples and comparative examples, unless otherwise specified, % represents wt%, i.e., weight percentage. The reagents or instruments used without indicating the manufacturer are all conventional reagent products that can be obtained commercially.

[0043] Cationic hyaluronic acid, molecular weight 200kDa, degree of substitution 10%, from Bloomage Biotechnology.

[0044] Ergothioneine: from Bloomage Biopharm.

[0045] Hyaluronic acid: from Bloomage Biopharmaceuticals.

[0046] Example 1

[0047] 1. Experimental samples:

[0048] 2% minoxidil solution: minoxidil finished product purchased directly (active substance concentration is 2%).

[0049] 6% cationic hyaluronic acid solution: weigh 0.6 g of cationic hyaluronic acid, dissolve it in 10 mL of PBS, and mix well to obtain a 6% cationic hyaluronic acid solution.

[0050] 6% hyaluronic acid + hydroxypropyltrimethylammonium chloride (molar ratio 10:1) solution: weigh 0.58 g of hyaluronic acid with a molecular weight of 200 kDa (from Bloomage Biotechnology) and 0.02 g of hydroxypropyltrimethylammonium chloride, dissolve in 10 mL of PBS, and mix well to obtain a 6% hyaluronic acid + hydroxypropyltrimethylammonium chloride (molar ratio 10:1) solution.

[0051] 2. Collect human dermal papilla cells (BNCC360091) in logarithmic growth phase and culture at a cell density of 1×10 5 Each well was inoculated into a 24-well plate.

[0052] 3. Sample loading: After culturing in an incubator (37°C, 5% CO2) for 24 hours, the samples were tested according to the groups in Table 1. The DHT stimulation model was constructed as follows: 1×10 5 Cells were inoculated into 24-well plates at a seeding density of 100 μL / well and incubated overnight in an incubator (37°C, 5% CO2). When the cell plating rate in the 24-well plate reached 40% to 60%, 800 μL of cell culture medium was added to all groups, and 100 μL of 10×DHT working solution (concentration of 10 μg / mL) was added to the other groups except the blank control group. Then 200 μL of PBS was added to the blank control group, 100 μL of PBS was added to the negative control group, 100 μL of 2% minoxidil solution was added to the positive control group, 100 μL of 6% cationic hyaluronic acid solution was added to the experimental group 1, and 100 μL of 6% hyaluronic acid + hydroxypropyltrimethylammonium chloride (molar ratio 10:1) solution was added to the experimental group 2. After the addition of the sample, the plate was shaken left and right to mix the drugs in the plate. Three duplicate wells were set for each group. The final concentration of minoxidil in the positive control group was 0.2%, the final concentration of cationic hyaluronic acid in experimental group 1 was 0.6%, and the final total concentration of hyaluronic acid and hydroxypropyltrimethylammonium chloride in experimental group 2 was 0.6%.

[0053] Table 1 Experimental conditions and groups

[0054]

[0055]

[0056] 4. Sample collection: After adding the sample, continue culturing in an incubator (37°C, 5% CO2) for 24 hours and collect the culture medium.

[0057] 5. Detection: Human VEGF ELISA kit was used to detect the VEGF content in the culture medium. The specific detection method was carried out according to the instructions in the kit.

[0058] 6. Data analysis and test results

[0059] The obtained data were statistically analyzed using the t-test method, and the results are shown in Table 2 below:

[0060] Table 2 VEGF content (pg / mL)

[0061]

[0062] Note: When using the t-test method for statistical analysis, compared with the BC group, the significance is indicated by #, P-value < 0.05 is indicated by #, P-value < 0.01 is indicated by ##, and P-value < 0.001 is indicated by ###; compared with the NC group, the significance is indicated by *, P-value < 0.05 is indicated by *, P-value < 0.01 is indicated by **, and P-value < 0.001 is indicated by ***. Compared with the cationic hyaluronic acid group, the significance is indicated by ▲, P-value < 0.05 is indicated by ▲, and P-value < 0.01 is indicated by ▲▲.

[0063] According to the data in Table 2, compared with the negative control group, cationic hyaluronic acid and the physical mixture of hyaluronic acid and hydroxypropyltrimethylammonium chloride have a significant effect on promoting vascular endothelial growth factor VEGF in hair papilla cells at a dosage concentration of 0.6% (m / v). Compared with the physical mixture of hyaluronic acid and hydroxypropyltrimethylammonium chloride, the cationic hyaluronic acid synthesized by the chemical grafting process has a more significant effect on promoting VEGF synthesis (p<0.01), proving that cationic hyaluronic acid has a synergistic effect in promoting hair growth.

[0064] Example 2

[0065] 1. Experimental samples:

[0066] Preparation of 2% minoxidil solution: directly purchase the minoxidil finished product (active substance concentration is 2%).

[0067] 6% cationic hyaluronic acid solution: weigh 0.6 g of cationic hyaluronic acid, dissolve it in 10 mL of PBS, and mix well to obtain a 6% cationic hyaluronic acid solution.

[0068] Preparation of 6% ultrapure ergothioneine: weigh 0.6 g ultrapure ergothioneine, dissolve it in 10 mL PBS, and mix well to obtain.

[0069] 6% cationic hyaluronic acid + ergothioneine solution: cationic hyaluronic acid and ultrapure ergothioneine were weighed in mass ratios of 10:1, 5:1, 1:1, 1:5, and 1:10, respectively, with a total mass of 0.6 g for both, and then dissolved in 10 mL PBS and mixed evenly to obtain cationic hyaluronic acid + ergothioneine solutions with different mass ratios.

[0070] 2. Collect human dermal papilla cells in logarithmic growth phase and set the cell density at 1×10 5 Each well was inoculated into a 24-well plate.

[0071] 3. Sample loading: After culturing in an incubator (37°C, 5% CO2) for 24 hours, the samples were tested according to the groups in Table 3. The DHT stimulation model was constructed as follows: 1×105 Cells were inoculated into 24-well plates at a seeding density of 100 μL / well and incubated overnight in an incubator (37°C, 5% CO2). When the cell plating rate in the 24-well plate reached 40% to 60%, 800 μL of cell culture medium was added to all groups, and 100 μL of 10×DHT working solution (concentration of 10 μg / mL) was added to all groups except the blank control group. Then 200 μL of PBS was added to the blank control group, 100 μL of PBS was added to the negative control group, 100 μL of 2% minoxidil solution was added to the positive control group, 100 μL of 6% ergothioneine solution was added to experimental group 1, 100 μL of 6% cationic hyaluronic acid solution was added to experimental group 2, and 100 μL of 6% cationic hyaluronic acid + ergothioneine (mass ratio 100 μL) was added to experimental group 3. 10:1) solution, experimental group 4 adds 100 μL of 6% cationic hyaluronic acid+thioneine (mass ratio 5:1) solution, experimental group 5 adds 100 μL of 6% cationic hyaluronic acid+thioneine (mass ratio 1:1) solution, experimental group 6 adds 100 μL of 6% cationic hyaluronic acid+thioneine (mass ratio 1:5) solution, experimental group 7 adds 100 μL of 6% cationic hyaluronic acid+thioneine (mass ratio 1:10) solution.After sample addition is completed, the orifice plate is shaken left and right so that the orifice plate is mixed with medicine, and 3 multiple holes are set in each group.Wherein, the final concentration of minoxidil in positive control group is 0.2%, and the final concentration of thioneine in experimental group 1 is 0.6%, and the final total concentration of cationic hyaluronic acid in experimental group 2 is 0.6%, and the final total concentration of cationic hyaluronic acid and thioneine in experimental group 3-experimental group 7 is 0.6%.

[0072] Table 3 Experimental conditions and groups

[0073]

[0074] 4. Sample collection: After adding the sample, continue culturing in an incubator (37°C, 5% CO2) for 24 hours and collect the culture medium.

[0075] 5. Detection: Human VEGF ELISA kit was used to detect the VEGF content in the culture medium. The specific detection method was carried out according to the instructions in the kit.

[0076] 6. Data analysis and test results

[0077] The obtained data were statistically analyzed using the t-test method, and the results are shown in Table 4 below:

[0078] Table 4 VEGF content (pg / mL)

[0079]

[0080]

[0081] Note: When using the t-test method for statistical analysis, compared with the BC group, the significance is indicated by #, P-value < 0.05 is indicated by #, P-value < 0.01 is indicated by ##, and P-value < 0.001 is indicated by ###; compared with the NC group, the significance is indicated by *, P-value < 0.05 is indicated by *, P-value < 0.01 is indicated by **, and P-value < 0.001 is indicated by ***. Compared with the ergothioneine group, the significance is indicated by ▲, P-value < 0.05 is indicated by ▲, and P-value < 0.01 is indicated by ▲▲. Compared with the cationic hyaluronic acid group, the significance is indicated by ▼, P-value < 0.05 is indicated by ▼, and P-value < 0.01 is indicated by ▼▼.

[0082] According to the data of Table 4, compared with the negative control group, cationic hyaluronic acid and thioneine are compounded in the ratio of 10:1, 5:1, 1:1, 1:5 and 1:10, and all have the effect of significantly promoting vascular endothelial growth factor VEGF in hair papilla cells. Cationic hyaluronic acid and thioneine are significantly different compared with single components under the ratio combination of 1-5:5-1, and the composition can synergistically promote vascular endothelial growth factor VEGF, thereby having a synergistic effect when promoting hair growth.

Claims

1. A composition, characterized in that The composition comprises the following components: a) at least one cationic hyaluronic acid, b) at least one ergothioneine.

2. The composition according to claim 1, characterized in that The mass ratio of the components a) and b) is 1:0.2-5.

3. The composition according to claim 1 or 2, characterized in that Also included are acceptable excipients.

4. Application of cationic hyaluronic acid in the preparation of products that promote the secretion of vascular endothelial growth factor (VEGF).

5. Use of cationic hyaluronic acid in the preparation of hair care and / or hair loss prevention and / or hair growth promotion products.

6. Application of cationic hyaluronic acid and ergothioneine in the preparation of products for promoting the secretion of vascular endothelial growth factor (VEGF).

7. The use according to claim 6, characterized in that: The mass ratio of cationic hyaluronic acid to ergothioneine is 1:0.2-5.

8. Use of the composition according to any one of claims 1 to 3 in the preparation of hair care and / or hair loss prevention and / or hair growth promotion products.

9. A method for hair care and / or hair loss prevention and / or hair growth promotion, comprising administering cationic hyaluronic acid or the composition according to any one of claims 1 to 3 to a subject.

Images